Bruker (BRKR) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.22%. A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.65 per share when it actually produced earnings of $0.70, delivering a surprise of 7.69%.Over the last four quarters, the ...

Exhibit 99.1 Bruker Reports First Quarter 2024 Financial Results • Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy • Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 • Updated FY 2024 guidance: • Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13% yoy. • Organic revenue growth maintained at 5% to 7% yoy • CER revenue growth of 12% to 14% yoy, including cl ...

We are in the middle of the first-quarter 2024 earnings season, with numerous MedTech bigwigs having already released first-quarter results. Per the latest Earnings Preview, quarterly results of the Medical sector are projected to decline year over year, affected by the ongoing macroeconomic headwinds, primarily in the form of worldwide geopolitical issues and healthcare labor shortages.Going by the broader Medical sector’s scorecard, 16.7% of the companies in the Medical sector, constituting 32.6% of the s ...

In its upcoming report, Bruker (BRKR) is predicted by Wall Street analysts to post quarterly earnings of $0.46 per share, reflecting a decline of 28.1% compared to the same period last year. Revenues are forecasted to be $723.84 million, representing a year-over-year increase of 5.6%.The consensus EPS estimate for the quarter has been revised 0.7% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during t ...

Bruker Corporation (BRKR) is likely to grow in the coming quarters, backed by the strong potential of the Bruker Scientific Instruments (“BSI”) Nano Group. In BioSpin, strength across end markets, including the new IDS (integrated data solutions) business, sounds encouraging for the company. The CALID Group has also been making decent progress lately, primarily due to the strong demand for differentiated instruments.Meanwhile, exposure to currency fluctuations, as well as competitive challenges, can potenti ...

Bruker (BRKR) continues to grow, banking on its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. The stock carries a Zacks Rank #2 (Buy) currently.Bruker’s CALID Group has been making decent progress lately, primarily because of the strong demand for differentiated instruments. The group is benefiting from sustained growth in the mass spectrometry business, including FT-IR, Near IR and Raman molecular spectroscopy product lines. Bruker’s timsTOF platform cont ...

NanoString’s GeoMX Digital Spatial Profiler was at the heart of a patent lawsuit filed by 10x Genomics. (NanoString Image)NanoString announced Wednesday that it will be acquired by Bruker, ending the company’s restructuring process that included a Chapter 11 bankruptcy plan. Bruker, a Massachusetts-based publicly traded life sciences research and diagnostic giant founded in 1960, will pay $392.6 million to buy Seattle-based NanoString. The deal is expected to close next month. NanoString said in February th ...

Bruker Corporation (BRKR) introduced novel magnet technology and analytical solutions at the 65th ENC. The novel technology facilitates the widespread application of NMR in academic basic and clinical research, as well as in drug discovery and development by biopharmacies and process analytical technologies (PAT).The latest development will fortify Bruker’s Scientific Instruments (BSI) BioSpin segment.More on New Magnet TechnologyAt the 65th ENC, with a complete one-year liquid helium hold-time, more than d ...

合作关系 - Biognosys和Alamar将在非小细胞肺癌研究方面展开合作[1] - Biognosys和Alamar将共同开展研究合作，探索血浆生物学[3] 服务提供 - Biognosys将提供NULISA Assay Services，为研究人员提供有价值的生物过程洞察[2] 技术创新 - Biognosys和Alamar的合作旨在推动蛋白质组学研究，为精准医学提供创新技术[4]

Shares of Bruker Corporation (BRKR) reached a new 52-week high of $94.86 on Mar 21 before closing the session marginally lower at $94.27.In the past year, this Zacks Rank #3 (Hold) stock has risen 25.9% against a 1.1% decline of the industry and the S&P 500 composite’s rise of 32.2%.Over the past five years, Bruker registered earnings growth of 13%, comparing favorably with the industry’s 5.1% rise. The company has an expected long-term earnings growth rate of 14.4%. Bruker’s earnings surpassed the Zacks Co ...